Skip to content
2000
Volume 11, Issue 2
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Diabetic macular edema (DME) is the leading cause of moderate vision loss in diabetics. Modalities to image and monitor DME have evolved much in the last decade. Systemic control is the most important part of management. Available ocular management options include intravitreal antivascular endothelial growth factor (anti-VEGF) agents, laser, steroids (intravitreal or peribulbar), vitrectomy, topical medications and others. Anti-VEGF agents are increasingly being used in clinical practice with good clinical response and are currently the preferred mode of treatment worldwide.

Loading

Article metrics loading...

/content/journals/cdr/10.2174/1573399811999150324120640
2015-06-01
2025-05-21
Loading full text...

Full text loading...

/content/journals/cdr/10.2174/1573399811999150324120640
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test